Searchable abstracts of presentations at key conferences in endocrinology

ea0016p542 | Obesity | ECE2008

The sirtuin activating compound resveratrol decreases GH transcription

Monteserin Jose Luis , Stalla Johanna , Stalla Gunter , Theodoropoulou Marily

Caloric restriction is the best known experimental procedure that extends lifespan and resistance to aging-related diseases. Part of these actions was found to be mediated by the NAD-dependent histone deacetylase Sir2/Sirt1. Resveratrol is a polyphenol found in the skin of grapes, which was identified as a Sirt1 activator and subsequently proposed as a caloric restriction mimetic. The aim of the present study was to determine how resveratrol affects the GH axis, which is centr...

ea0063p268 | Pituitary and Neuroendocrinology 1 | ECE2019

The PATRO adults study of Omnitrope® for the treatment of adult patients with growth hormone deficiency: latest safety results

Beck-Peccoz Paolo , Hoybye Charlotte , Murray Robert D , Simsek Suat , Zabransky Markus , Zouater Hichem , Stalla Gunter

Introduction: PATRO Adults is an ongoing, longitudinal, noninterventional study assessing the long-term safety and efficacy of Omnitrope® (Sandoz; recombinant human growth hormone [rhGH]), among adults with severe growth hormone deficiency (GHD) treated in routine clinical practice in European countries. Omnitrope® was approved by the European Medicines Agency (EMA) in 2006, representing the first biosimilar approved by the EMA. We report the la...

ea0049ep912 | Neuroendocrinology | ECE2017

The PATRO adults study of Omnitrope for the treatment of adult patients with growth hormone deficiency: latest results

Beck-Peccoz Paolo , Hoybye Charlotte , Murray Robert , Simsek Suat , Zabransky Markus , Stalla Gunter

Introduction: The ongoing, international, open, longitudinal, non-interventional study, PATRO Adults, aims to determine the long-term safety and efficacy of Omnitrope® (Sandoz), a recombinant human growth hormone (rhGH). Safety data from an interim analysis are presented here.Methods: Eligible patients are male or female adults who are receiving treatment with Omnitrope® and who have provided informed consent. Patients tre...

ea0041gp119 | Neuroendocrinology | ECE2016

Hypoxia-inducible factor 1α triggers growth hormone synthesis in acromegalic tumors

Lucia Kristin , Monteserin-Garcia Jose , Buchfelder Michael , Renner Ulrich , Stalla Gunter , Theodoropoulou Marily

Acromegaly is caused by excessive growth hormone (GH) secretion frequently due to GH-secreting pituitary tumors. Acromegalic tumors (ACRO) display reduced microvascular density versus normal pituitaries, suggesting they are under hypoxic conditions. Under hypoxia, tumors gain a survival advantage by stabilizing the transcription factor known as hypoxia-inducible factor 1 alpha (HIF1a). Western blot screening of ACRO (n=40) revealed significantly higher HIF1a protein l...

ea0041gp128 | Neuroendocrinology | ECE2016

Latest results from the PATRO adults study of Omnitrope® for the treatment of adult patients with growth hormone deficiency

Beck-Peccoz Paolo , Hoybye Charlotte , Murray Robert , Simsek Suat , Leal-Cerro Alfonso , Zabransky Markus , Stalla Gunter

Introduction: PATRO adults is an international, longitudinal, non-interventional study of the long-term safety and efficacy of recombinant human growth hormone (rhGH; Omnitrope®, Sandoz). The study will provide additional data on the long-term safety of rhGH in adult patients with severe GH deficiency (GHD). Here, we present safety data from an interim analysis.Methods: Eligible patients are adults who are receiving treatment with Omnitro...

ea0041gp133 | Obesity | ECE2016

The ubiquitin-like pathway neddylation controls adipocyte differentiation, obesity and metabolism

Bauder Corinna , Labeur Marta , Vogl Annette , Wolfel Barbara , Wurst Wolfgang , Stalla Gunter , Refojo Damian

The ubiquitin-proteasome cascade has been described as a critical factor in adipocyte biology, insulin signaling and obesity, but the function of Nedd8, the ubiquitin-like protein with the closest homology to ubiquitin, remains unknown. Using 3T3-L1 preadipocyte cells, we found that MLN-4924, a specific neddylation inhibitor, blocks adipocyte differentiation. Screening for signaling and transcriptional factors driving adipogenesis, we found that neddylation blockade inhibits t...

ea0041ep488 | Diabetes complications | ECE2016

Does type 2 diabetes mellitus affect bone mineral density?

Sarmadi Payam , Bazrafshan Behnaz , Bazrafshan Hamidreza , Stalla Gunter , Aghaei Mehrdad , Shadpourdashti Hossien , Mousavi Fatemeh , Eftekharie Mamak

Introduction: The effects of diabetes mellitus (DM) on bone mineralization and osteoporosis is not well established. While reduction in bone mineral density in patients with type 1 diabetes is almost confirmed, effects of type 2 diabetes on bone health is still unclear. However in some studies bone mineral density (BMD) was suggested to be normal or elevated, epidemiological reports have shown an increased risk of fracture among patients with type 2 diabetes. This paper tries ...

ea0041ep859 | Pituitary - Basic | ECE2016

A C-terminal inhibitor of HSP90 decreases GH-promoter activity and growth hormone secretion in a cellular model of somatotrophinomas

Ciato Denis , Regazzo Daniela , Occhi Gianluca , Scaroni Carla , Stalla Gunter , Paez-Pereda Marcelo

Heat shock protein 90 (HSP90) plays a pivotal role in maturation and stabilization of proteins in conditions of stress. Many HSP90 client proteins are involved in oncogenic signaling and cancer progression, therefore HSP90 inhibitors have a potential as pharmaceutical agents. We reported a strong HSP90 overexpression in corticotroph adenomas and the treatment with C-terminal HSP90 inhibitors has potent anti-tumorigenic and anti-secretory effects in these tumors in vitro</e...

ea0041ep860 | Pituitary - Basic | ECE2016

Evidence for better response to somatostatin analogues in acromegalic patients treated with metformin

Winkelmann Moritz , Geraedts Victor , Lucia Kristin , Stormann Sylvere , Buchfelder Michael , Stalla Gunter , Theodoropoulou Marily

Somatostatin analogues (SSA) are the mainstay of pituitary-targeted pharmacological treatment in acromegaly, but are characterized by high incidence of resistance in half of cases. The successful management of acromegaly involves in addition to targeting biochemical control the treatment of the metabolic comorbidities and hypopituitarism. In this study we analysed the impact of the concomitant antidiabetic treatment and hormone replacement on the response to SSA. Data were col...

ea0037ep765 | Pituitary: clinical | ECE2015

Effectiveness and tolerability of lanreotide in acromegaly: a German database analysis

Dimopoulou Christina , Stormann Sylvere , Schopohl Jochen , Faust Johanna , Stalla Gunter Karl

Introduction: Somatostatin analogues (SSA) present the treatment of choice in patients with previously poorly controlled acromegaly.Methods: We conducted a retrospective analysis of acromegalic patients enrolled in the Network of Excellence for Neuroendocrine Tumors Munich and treated with the SSA lanreotide.Results: Fifty-six acromegalic patients (25 females; mean age 59 years; 33 with macroadenoma) switched to lanreotide from pre...